Signal from the log
R1 Therapeutics
3 M$ · Series A · United States · Biotech
R1 Therapeutics, en Californie, développe AP306, une molécule qui bloque trois transporteurs du phosphate dans l'intestin, pour les dialysés dont le phosphore sanguin reste trop haut malgré les traitements actuels. Samsara BioCapital apporte 3 M$, ce qui porte la série A à 80,5 M$ avant des résultats de phase 2b attendus au premier semestre 2027.
Verified
Announced on , logged by the watch of 30 September 2026.
- Operation
- Funding round
- Announced amount
- 3 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Samsara BioCapital
Provenance
Source pulse2
Logged on 30 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.